ABSTRACT

Over the past two decades, global health innovation has delivered important new tools for use in low- and middle-income countries (LMICs) and saved many lives. Nonetheless, the current innovation ecosystem suffers from significant limitations that are likely to worsen with aid transition. These include a dependence on donor push funding, which can distort research and development (R&D) priorities and crowd out private sector investment; “product pileup” of donor-funded innovations with little actual demand in LMICs; low diffusion and uptake of cost-effective innovations, leaving potential health gains on the table; and remaining gaps in R&D for major LMIC health needs, such as tuberculosis.

In this note we seek to better diagnose and address these challenges through a demand-side approach—that is, to consider how better payer policy in LMICs, supported by international actors, can create a more effective and sustainable ecosystem for developing and disseminating health innovation to individuals in need. We conclude with a proposal to establish an Innovation Uptake Institute to serve as an honest broker between country payers and suppliers, helping payers to bolster their strategic capacity through market intelligence, capacity-building, and shared technical resources.

INTRODUCTION

Financing patterns for global health are changing rapidly, with important implications for health technology innovation. The number of low-income countries is shrinking (there are now 31 based on the latest World Bank classification), while the collective GDP of the Emerging 7 (E7) economies is set to overtake the G7 by 2030; in turn, aid is receding across low- and middle-income countries (LMICs). Recent CGD analysis suggests that governments are slow to increase expenditure on public health products following aid transition; instead, private expenditure—mostly out of pocket—rises quickly to meet growing demand. Scarce government expenditure is often not targeted to the most cost-effective health interventions but instead used to cover curative and higher-level care demanded by vocal,
growing, urban populations. This spend is largely unorganized, often inefficient, and almost always inequitable.

These expenditure and behavioural patterns threaten both (1) the rapid uptake of cost-effective innovations; and (2) research and development (R&D) expenditure for health innovation targeting the needs of LMICs. When countries fail to adequately fund health innovation and/or systematically evaluate the appropriateness of new products for government subsidy or purchase, they also create market uncertainty and fail to send clear market signals, dissuading the private sector from investing its resources in R&D or the expansion of needed manufacturing capacity. And once innovative products come to market, countries are likely to make inappropriate adoption or non-adoption decisions—simultaneously using scarce resources to fund expensive treatments for a select, articulate, few while overlooking new cost-effective innovations with the potential to transform their citizens’ health.

In this note we seek to better diagnose and address these challenges through a demand-side approach—that is, to consider how better payer policy in LMICs, supported by international actors, can create a more effective and sustainable ecosystem for developing and disseminating health innovation to individuals in need. We first review the current state of innovation and uptake across LMICs, highlighting points of dysfunction. In this context, we identify the lack of coherent and strategic payer policy as a key constraint to widespread uptake—one that is largely unaddressed by current donor initiatives. We conclude with a proposal to establish an Innovation Uptake Institute (IUI) to serve as an honest broker between country payers and suppliers, helping payers to bolster their strategic capacity through market intelligence, capacity-building, and shared technical resources.

TODAY’S INNOVATION AND UPTAKE ECOSYSTEM

Today, most innovative health products that penetrate LMIC markets do so through one of two channels. The first channel—a limited private sector market—primarily targets the richest subgroups of LMICs with products that were already developed to serve more lucrative high-income markets. The wealthy in these countries can pay out of pocket or via some form of private insurance, but poorer populations remain largely neglected. And many innovative products never even reach LMIC markets; for example, of the 330 new chemical entities launched worldwide between 2007 and 2016, a recent CGD analysis found that only 21 were available at any price in French West Africa.

More commonly, donor push funding—primarily from the Bill & Melinda Gates Foundation and typically channelled through product development partnerships—helps maintain an upstream innovation pipeline for diseases of the poor. Downstream market shaping efforts and pooled procurement (using development assistance for health) facilitate some degree of product uptake, but at levels that frustrate donors, given the size of the investments they have made.
However, the current model of extended and intensive push funding is problematic for several reasons:

- It can crowd out (as well as complement) private investment;
- It substitutes global development actors for national LMIC payers in setting innovation priorities;
- It may generate products that are inappropriate or unaffordable for the intended beneficiaries, who may nonetheless be pressured to adopt them;
- Progress remains fundamentally vulnerable to the whims and resource constraints of a few large foundations and donor governments;
- With many high-burden countries facing a transition from external health assistance, it is unlikely that donors will expand or even maintain existing push initiatives.

For now, despite ongoing push investments, major gaps in the innovation landscape remain. For example, innovation for new tuberculosis (TB) drugs is badly underfunded and largely reliant on public and philanthropic resources, (primarily the US government and the Bill & Melina Gates Foundation). In the absence of coordinated demand and a credible market, private investment in TB R&D has been in steady decline; strikingly, multinational companies invest less than 0.05 percent of total private R&D money on the world’s most deadly infectious disease.

Even when push-funded innovative products targeting LMIC health needs make it to market, adoption can sometimes be slow or nonexistent—meaning anticipated health gains go unrealized. For example, Bedaquiline was approved by the US Food and Drug Administration (FDA) in 2012 and by the European Medicines Agency (EMA) in 2014 as a breakthrough treatment for drug-resistant TB. However, the WHO subsequently issued guidance on the use of Bedaquiline with restrictive, against-the-label indications (in 2013 and again in 2016). As a result, J&J (the manufacturer) is facing a limited market, exacerbated by weak country-level procurement mechanisms, no/limited volume commitments, high production costs, and calls for genericization by civil society, all leading to weak market penetration and shortages (e.g., China).

On the demand side, there are some early signs of progress, but they are not, by themselves, sufficient to drive innovation uptake. Some countries are beginning to pool expenditure; others are building strategic, evidence-informed processes to drive product selection, the design of benefits packages, and procurement; and some others are making progress on both fronts. Of particular importance are the institutionalisation of Health Technology Assessment processes and consideration of pooled procurement mechanisms; though in many countries these efforts remain nascent, small-scale, or poorly integrated into the procurement process. Regulatory harmonisation has also been a major policy innovation but remains slow-moving in practice. Finally, WHO policy guidance can play a helpful role in informing product selection—but because guidance documents are developed centrally,

---

2 See here, here, here and here for some examples.
3 India, for example, is beginning to legislate use of HTA in the context of its fast expanding “Modicare.” China has also used basic HTA methods to inform its vast and growing procurement experiment (4+7); it now regularly uses HTAs to inform listing and pricing negotiations with domestic and multinational companies through the Medical Insurance Administration.
they are understandably unable to fully reflect local feasibility constraints, priorities, and budgets, constraining their wide applicability. And despite the great degree of uncertainty on the comparative effect of new treatments in emerging markets, there is little appetite for experimenting with the use of real world evidence or market entry agreements now routinely used in high-income countries (HICs) systems.

The combined weight of these forces suggests a grim outlook for future global health innovation and uptake. We are likely to see:

A continuing and deteriorating product pileup;

- Advocacy for voluntary or compulsory licensing and genericization of any successful innovations, further reducing the appetite for private investment in priority areas;

- Gradual (but slow) expansion of payer-side HTA-type mechanisms in LMICs, likely to be used reactively in a cost-containment role;

- Investment of scarce LMIC domestic healthcare dollars in high-cost, high-tech innovation despite weak systems and professional skills (e.g., dialysis or breast cancer treatment) while continuing to pay high prices even for commoditised products.

UNRAVELLING THE BLACK BOX OF PAYER POLICY

One key missing ingredient in this ecosystem—and the opportunity to change the current trajectory—is the understudied black box of payer policy (Figure 1). By building coordinated, evidence-informed, and well-governed purchasing processes, LMICs payers can increase the efficiency of their spending; improve the health of their populations; ensure wide access to and uptake of cost-effective health innovations; and incentivize private-sector R&D investments that target local health needs.

Figure 1. Unpacking the black box of payer policy
Importantly, however, payer policy cannot fully substitute for other steps in the value chain (Figure 1) that drive innovation uptake. Payer policy is most effective when complemented by a robust regulatory environment, improved fiscal space, and strong delivery platforms; investments in relevant policy initiatives in these areas by donors, manufacturers, regulators and the WHO should therefore be continued and strengthened.

Specifically, we see a need to strengthen country payers through (1) better national purchasing functions; (2) effective support from international bodies and institutions to inform national purchasing; and (3) international cooperation, with large middle-income countries at the helm, to coordinate and/or pool demand. Ten tools stand out as particularly promising:

1. Health Technology Assessment (HTA) for timely adoption and reimbursement decisions, helping countries to assess whether innovations will be appropriate for local use and adopt a proactive and rapid approach to adoption and scale-up. Further investigation is needed to understand the support countries need to implement HTA; the extent to which this support is already available through existing donor support programmes (including iDSI); and potential lessons from the implementation and use of HTA in LMICs to date, including issues of capacity, data, and regional economies of scale and scope.

2. Horizon-Scanning to help to identify innovations that will be available within a couple of years subject to successful conclusion of development programmes. Horizon-scanning is common in HICs—increasingly through cross-country collaboration (e.g., see here for a major European partnership). In LMICs, its application would help payers plan early HTA to inform an adoption decision, for example.

3. Value (from the payer perspective)-based tiered pricing using HTA, to inform effective negotiation between multinational companies and country payers and expand access to innovative products at locally cost-effective affordable prices and to rationalize country cofinancing of donor-procured health products. The potential to successfully apply tiered pricing would depend on several prerequisites including price negotiation through a national payer able to signal willingness to pay based on budgetary constraints; acceptance of the current patent system for most products; and a competitive, quality-assured generics market resulting in significant price reductions following patent expiry.

4. Pooled and cooperative procurement to increase negotiating power, send stronger market signals, and reduce transaction costs, potentially to include intelligence sharing, joint negotiations, and joint contracts across countries. Pooled or cooperative procurement could also incorporate HTA, horizon scanning, and tiered pricing functions, with HTA-informed joint negotiations for specific types of products (e.g., for on-patent cancer products; orphan drugs; products with high manufacturing costs; or products with past experience of significant supply shortages, such as insulin). Country coalitions could also consider a contractual advance market commitment to buy specific innovative products, as we have explored in our MVAC concept. Such innovative contracting arrangements offer a potential bridge for LMIC pharmaceutical markets to become more like “conventional” HIC markets.

---

4 See Chalkidou, Yadav, Silverman, and Claxton, 2020 (forthcoming). Value Based Tiered Pricing for UHC: An Idea Worth Revisiting, for further discussion. Discussions on Tiered Pricing especially in the context of co-financing and aid transition are linked with global procurement architecture and market shaping. They are of direct relevance to GFATM and Gavi as well as to DFID and other national aid bodies.
5. Budget planning mechanisms to ensure country purchase readiness for cost-effective innovations.

6. Market Entry Agreements as used in HICs\(^5\) to help address budget constraints and uncertainty, for example about the health gain that will be delivered or the number of patients that will be treated. Market Entry Agreements can be linked to conditional reimbursement and the collection of further evidence (such as real-world evidence and data) to enable a subsequent HTA reassessment of product value.

7. Private multinational companies’ efforts to improve access in-country, beyond pricing (e.g., through the strengthening of local supply chains).

8. Appropriate design of domestic industrial and science policy to enable innovation development and diffusion.

9. Scientific advice programmes (like those developed in HICs)\(^6\), bringing together regulators and HTA bodies to explore the evidence required to gain rapid market entry and achieve efficient use by the health system. In LMICs it will be particularly important to involve payers in these discussions given (i) budget constraints and (ii) the need for service delivery-related uptake measures to be put in place for many programmes to succeed.

10. Market intelligence templates to inform product launches in a range of LMIC markets. Exploring gaps in the availability of data will be important here, as templates will need to use epidemiological burden of disease information coupled with estimates of locally relevant effect size from any target product profile, together with estimates of the incremental costs associated with adoption of the innovation.

Table 1 maps the problems identified earlier onto the 10 solution tools set out above. We do so by grouping the problems into the three component parts of the product lifecycle:

- Discovery and development (LMICs need more of the “right” new products and fewer “wrong” ones)
- Market entry (Products do not get through the barrier of obtaining a licence, or a price, or a listing for public procurement and reimbursement)
- Delivery/uptake (Products do not get used in an optimal way to meet local health need)

\(^5\) For a discussion on LMICs see here.

\(^6\) Alignment with payers (HTA) and regulators (early scientific advice) is of the essence as is learning from early experience of European nations in this space (e.g. see here and here).
Table 1. Mapping challenges with support tools that can offer solutions

<table>
<thead>
<tr>
<th>Identified Challenges</th>
<th>Applicable Support Tools</th>
</tr>
</thead>
</table>
| Discovery and Development (LMICs need more of the “right” new products and fewer “wrong” products) | • Scientific advice/early HTA  
• Market Intelligence Templates  
• Appropriate use of domestic industrial/science policy  
• Strategic procurement and contracting including Value-Based Advance Market Commitment (MVAC)-type solutions |
| • Lack of clear market signals limits (i) efficient, equitable, uptake and, therefore, (ii) private sector investment in R&D and manufacturing to deliver innovative products to LMICs.  
• Donor-funded push funding may be generating products that are inappropriate or unaffordable for the intended beneficiaries, who may nonetheless be pressured to adopt them. Donor funding is also limited, and many high-burden countries face a transition from external health assistance.  
• Most multinational companies respond by focusing on out of pocket or richer population subgroups. Donor push funding has created upstream pipelines, but donor funded market shaping has had limited impact on uptake.  
• For now, despite ongoing push investments, major gaps in the innovation landscape remain. | |
| Market Entry (Products do not get through the barrier of obtaining a licence, or a price, or a listing for public procurement) | • Horizon-scanning  
• Value-based tiered pricing  
• Use of HTA  
• Pooled strategic procurement and contracting |
| • There is evidence of improved procurement, use of evidence informed HTA, and regulatory reform, but much more needs to be done.  
• LMICs need to spend more on health care, but, importantly, they need to spend money efficiently. | |
| Delivery/uptake (Products do not get used in an optimal way to meet local health need.) | • Budget planning tools  
• Use of Managed Entry Agreements and collection of credible real-world evidence  
• Role of private multinational companies in improving access in-country, beyond pricing  
• Pooled strategic procurement and contracting |
| • Tools used in HICs to facilitate and manage uptake, such as market entry agreements and the collection of real-world evidence, are rarely considered in LMICs.  
• Adoption of high-profile new interventions can sometimes be slow or nonexistent, and anticipated health gains often go unrealized. | |
THE WAY FORWARD: AN INNOVATION UPTAKE INSTITUTE (IUI)

The opportunity cost of inaction is significant. To extricate the global community from the dysfunctional status quo, we propose a concerted, multi-stakeholder effort centred around and led by a new entity, the Innovation Uptake Institute (IUI). The IUI would serve as:

- a platform for engagement that sits between the demand and supply sides, as well as between development partners and civil society;

- an observatory for independent and context-sensitive market research and intelligence sharing as a global public good; and

- a point of call for targeted problem solving and system strengthening as well as capacity building of a professionalised cadre of “intelligent purchasers and negotiators,” as countries set up their own mechanisms for assessing and rewarding value.

Such an institute would not be a panacea but would begin to address some of the challenges identified in the previous sections. The IUI would aim to crowd in private investment in disease areas currently deprioritised by conventional industry by quantifying potential market size and supporting better coordinated/pooled demand. We envision it having a broad remit, including products yet to be developed, under development, or already in the marketplace; and serving a broad coalition of country payers and development partners.

Most importantly, though the IUI would focus on demand-side strengthening, the IUI itself would be fiercely independent from both the demand and supply sides—from suppliers, payers, and advocates alike—in order for its products and support activities to be trusted and effective. In this way, the IUI is differentiated from typical market access functions, which are usually tasked with maximizing uptake of a product and related revenues. In contrast, the IUI will aim for optimal uptake of a technology from the point of view of LMIC societies, addressing problematic behaviour already observed on both the demand- and supply-sides that prevents access to cost-effective innovation. In some cases, it is payers that block or delay uptake of cost-effective products that their populations need. New HTA mechanisms can be used to block access and contain costs. In other cases, suppliers promote products whose prices, given their comparative effectiveness, do not represent good value for money within a given health system. IUI would seek to enable the most appropriate (timely, cost-effective, and clinically and culturally relevant) uptake of a given technology—with the understanding that not all innovations will or should be adopted in every environment.

Sitting downstream of regulation but working in close coordination with NEPAD and WHO’s GBT initiative, the Institute would carry out, commission, or encourage a series of activities critical to the equitable uptake of cost-effective and locally appropriate products. These efforts would both build national capacities for these functions as specific markets become wealthier and develop economies of scope by offering differentiated but comparable support to a number of countries. By bringing all these functions together, the Institute would offer innovators and payers the chance to leapfrog the bureaucratic obstacles often faced by their counterparts in HIC settings. Figure 2 offers a list of possible functions.

---

### Figure 2. Suggested Institute functions

<table>
<thead>
<tr>
<th>Function</th>
<th>Description</th>
</tr>
</thead>
</table>
| Early HTA | • Early HTA to inform product development strategies, launch, and pricing  
• Value-based AMCs as pull incentives, as per MVAC example for TB |
| Joint scientific advice with regulators | • Alignment to regulatory processes; timely and rigorous evidence on safety and comparative efficacy  
• Platform for piloting early joint scientific advice with national regulators and payers fast-tracking approvals and uptake where appropriate |
| Real World Data/ Evidence | • Invest in flagship RWE data platform and prospective generation and synthesis through pragmatic RCTs, disease and tech registers, economic models and using real-world billing data, costing and resource use, and Big Data |
| Coping with Uncertainty | • Methods and process development for dealing with uncertainty in data-poor settings  
• Field testing of Managed Entry Schemes and Coverage with Evidence Development for select products |
| HTA mechanisms | • Value-based pricing and price negotiations for single-source products  
• Cost-conscious guidelines and adaptation of global targets to local realities |
| Health Benefits Package design & alignment | • Health Benefits Package listing and budgeting as part of functioning delivery platforms (e.g. through DRGs or case payment) |
| Evidence-informed procurement | • Evidence-informed procurement incl regional pooling/Global Purchasing and auction models developed and evaluated with a view to guaranteeing volumes, supply and prices |
With the triple role of a convening platform, a data observatory, and a problem-solving resource, the Institute could offer:

- Targeted technical assistance and capacity strengthening for the important but oftentimes neglected functions of commodity procurement or HTA, with a particular focus to professionalising procurement and pricing/reimbursement by LMIC payers.

- Independent market research and intelligence and global public goods including horizon-scanning; market-shaping; product and geography specific knowledge products; and market intelligence on payer breakdown (e.g., donors, government, out-of-pocket) and the corresponding impact on uptake.

- An engagement platform to facilitate communication and build trust between country payers, development partners, and manufacturers—all the more important as countries gradually take control of their commodities budgets. Such a space does not currently exist, with partial exceptions of one-off projects and industry-run initiatives such as Access Accelerated.

**How would the IUI be financed?**

The Institute would need to pursue a mixed funding model, albeit with a dependence on donor grants at early stages and when targeting the poorest geographies with very limited ability to pay. Industry funding should also be available, given the importance of getting clear market signals, and, increasingly, country payer and private insurance, all in the context of very strong conflict management rules. A stakeholder board with paying constituents including bilateral donors and large payers (UK, Germany, China, India, Brazil, RSA); philanthropists (BMGF, OPP, CIFF); WHO; industry (from HIC and MIC); and investors (CDC, Bridges, IFC) could be considered, including membership from emerging market payer schemes. The IUI could also consider spinning off self-funded social enterprises to tackle specific functions. For example, one could imagine a social enterprise intermediary between payers and industry to oversee/assist with HTA; use HTA to facilitate price negotiations in a neutral space; and take a small cut of subsequent sales to cover operating costs.

IUI could be linked with world class universities and with select in-country units incubated in existing institutions (e.g., Africa CDC; regulator networks/NEPAD) with a remit to carry out analyses to inform early pilots including gathering economic and market access data and developing product launch plans for the selected pilots in collaboration with payer entities.

**CONCLUSION**

In a crowded, dysfunctional, and likely unsustainable global health innovation ecosystem, payer policy remains an understudied and neglected function within the innovation value chain. By systematically and strategically strengthening payer policy, potentially aided through the establishment of a dedicated Innovation Uptake Institute, the global health community can begin to address some of the deep challenges related to misaligned innovation and low uptake of new and cost-effective products—improving access and health outcomes across LMICs.
ACKNOWLEDGEMENTS

We are grateful for helpful feedback and suggestions from Prashant Yadav and Ganesh Ramakrishnan. All errors and omissions are our own.

KALIPSO CHALKIDOU is director of the global health policy program, and senior fellow at the Center for Global Development.

ADRIAN TOWSE is director emeritus, and senior research fellow at the Office for Health Economics.

RACHEL SILVERMAN is a policy fellow at the Center for Global Development.